First-Time Users of Weight-Loss Medicines Seek Lower Costs and Greater Convenience from Novo Nordisk and Eli Lilly Pills

Americans initiating weight-loss medicines for the first time are expressing preferences for lower costs and greater convenience, particularly with oral options from pharmaceutical companies Novo Nordisk and Eli Lilly. This information comes from interviews with seven doctors who specialize in obesity treatment.

The doctors noted these trends among new patients seeking effective and accessible therapies.

Novo Nordisk and Eli Lilly are key players in the development of weight-loss drugs, including pill formulations that offer alternatives to injections. Patients value the ease of oral administration, which reduces the need for needles or frequent medical visits.

The focus on affordability stems from the high list prices of these medications, often exceeding $1,000 per month without insurance coverage.

The seven specialists, who treat patients across various U.S. regions, observed that first-time users often compare options based on out-of-pocket expenses and daily usability. For instance, Novo Nordisk's Rybelsus is an oral semaglutide approved for diabetes but used off-label for weight loss, while Eli Lilly is advancing similar pill-based therapies.

These doctors emphasized that convenience influences adherence, as patients aim to integrate treatments into their routines without disruption. Background on these medicines includes their basis in GLP-1 receptor agonists, which mimic hormones to regulate appetite and blood sugar.

Novo Nordisk's Wegovy, an injectable version, received FDA approval for weight management in 2021, and Eli Lilly's Zepbound followed in 2023.

The shift toward pills addresses barriers like injection phobia, affecting a portion of potential users.